In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Pulmonary hypertension: progress in management, impact on outcomes
Session

Event : ESC Congress 2018

Topic : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure – Epidemiology, Prognosis, Outcome

  • Session type : Rapid Fire Abstracts
  • Date : 27 August 2018
  • Time : 10:30 - 12:00

10 presentations in this session

Fast screening breath analysis for diagnostics of pulmonary hypertension.

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : A Swinarew (Chorzow,PL)

Phenomapping to detect non-invasively patients with combined postcapillary pulmonary hypertension

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : O Raitiere (Rouen,FR)

Impact of comorbidity on outcome in CTD-associated pulmonary arterial hypertension: data from the Swedish Pulmonary Arterial Hypertension Registry

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : C Hjalmarsson (Gothenburg,SE)

Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : N Galie (Bologna,IT)

Comparison between paediatric and adult patients with pulmonary arterial hypertension

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : E Zuffa (Bologna,IT)

The emPHasis-10 quality of life score for pulmonary hypertension is a strong predictor of mortality

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : C Favoccia (Rome,IT)

Effects on Right Ventricular size and function by Riociguat in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (The RIVER Study)

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : AM Marra (Heidelberg,DE)

Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in pulmonary arterial hypertension and right heart failure

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : S Andersen (Aarhus C,DK)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are